Anthony King
I am a freelance science journalist based in Dublin, Ireland. I cover a variety of topics in chemical and biological sciences, as well as science policy, health and innovation.
My articles have appeared in Nature, Science, Cell, Chemistry World, New Scientist, the Irish Times, New York Times, EMBO Reports, Chemistry & Industry and more.
I enjoy writing on a wide breadth of subjects, from antibiotics to petrochemicals, bumblebees to asteroid composition, palaeontology to brain development. Previously I worked for a publishing company as a science editor.
My primary degree in science is from Trinity College Dublin and I hold a Master’s degree in science communications from Dublin City University.
- Research
How HIV drugs have changed over the decades
From one big pill that only prolonged lives a few months, through the 20 pills a day years to modern combination therapies, treating HIV is a science success story
- Research
Microbial enzymes cut a path towards universal blood for transfusions
Slicing off glycans revealed new, previously unknown antigens that must be removed to produce O-type blood
- News
Plastic chemicals review reveals thousands of compounds have little safety data
Existing scientific knowledge on hazards of plastic chemicals compiled in dossier for decision makers
- Research
Concerns raised over health effects of chemicals leaching from food packaging
Gene assays reveal disruption to cell receptors crucial for hormonal and metabolic control
- Feature
How microbes influence our brain health
Our gut microbiome has been linked to conditions such as Parkinson’s and Alzheimer’s. Anthony King reports on the connections
- Business
Chemours suspends chief and senior executives over accounting issues
Auditors to investigate issues around whistleblowing and financial management
- Business
Big deals confirm renewed interest in radiopharmaceuticals
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
- Research
Striking reptilian fossil discovered in 1931 found to be fake
280-million-year-old lizard ‘fossil’ was mostly painted on
- Business
Novo Holdings to buy contract manufacturer Catalent for $16.5 billion
Parent firm will then sell on three manufacturing sites to Novo Nordisk to boost capacity for diabetes and weight loss drugs
- Research
Rare medical transmission of Alzheimer’s disease from donor to patient discovered
Human growth hormone extracted from cadavers passed disease protein to at least five people
- Business
Nuclear power expansion plans highlight fuel bottlenecks
Western governments look to overcome Russian dominance of key uranium processing steps
- Business
Danaher completes $5.7 billion Abcam acquisition
Deal proceeded despite significant opposition from founder and ex-chief Jonathan Milner
- Business
Life-saving cancer gene therapy under investigation after being linked to rare secondary cancers
US drug agency examining six CAR-T therapies after reports of T-cell malignancies
- Business
Northvolt to bring sodium-ion batteries to European market
Swedish firm highlights cells’ cheap and sustainable materials for energy storage
- Business
Weight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments
- News
Irish PhD researchers left disappointed as stipend raise is just half of what was hoped for
Independent review recommended increasing stipends to €25,000 but they rose to just €22,000
- Research
Field study reveals banned pesticide sulfoxaflor had no effect on pollination by bumblebees
Work adds to nuanced picture of pesticide’s effect on pollinating insects
- Research
Genetic-editing of chickens protects them from catching the flu
Approach heralds new way to make animals resistant to disease
- Research
Mutation studies reveal how Antarctic octopus arms itself with cool enzyme
Understanding cold-tolerant enzyme could help with transplant organ preservation
- Research
’This is just the beginning’: RNA editing set to democratise viral engineering
Crispr-based system could ease development of novel RNA therapies